<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib74">
 <element-citation publication-type="journal" id="sref74">
  <person-group person-group-type="author">
   <name>
    <surname>Le</surname>
    <given-names>R.Q.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Yuan</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Shord</surname>
    <given-names>S.S.</given-names>
   </name>
   <name>
    <surname>Nie</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Habtemariam</surname>
    <given-names>B.A.</given-names>
   </name>
   <name>
    <surname>Przepiorka</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Farrell</surname>
    <given-names>A.T.</given-names>
   </name>
   <name>
    <surname>Pazdur</surname>
    <given-names>R.</given-names>
   </name>
  </person-group>
  <article-title>FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome</article-title>
  <source>Oncol.</source>
  <volume>23</volume>
  <year>2018</year>
  <fpage>943</fpage>
 </element-citation>
</ref>
